Department of Anesthesia, Mayo Clinic College of Medicine, Rochester, MN.
Department of Anesthesia, Mayo Clinic College of Medicine, Rochester, MN; Multidisciplinary Epidemiology and Translational Research in Intensive Care Study Group, Division of Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN.
Chest. 2013 May;143(5):1407-1413. doi: 10.1378/chest.12-1860.
Airway pepsin has been increasingly used as a potentially sensitive and quantifiable biomarker for gastric-to-pulmonary aspiration, despite lack of validation in normal control subjects. This study attempts to define normal levels of airway pepsin in adults and distinguish between pepsin A (exclusive to stomach) and pepsin C (which can be expressed by pneumocytes).
We performed a prospective study of 51 otherwise healthy adult patients undergoing elective extremity orthopedic surgery at a single tertiary-care academic medical center. Lower airway samples were obtained immediately following endotracheal intubation and just prior to extubation. Total pepsin and pepsin A concentrations were directly measured by an enzymatic activity assay, and pepsin C was subsequently derived. Pepsinogen/pepsin C was confirmed by Western blot analyses. Baseline characteristics were secondarily compared.
In all, 11 (22%; 95% CI = 9.9%-33%) had detectable airway pepsin concentrations. All 11 positive specimens had pepsin C, without any detectable pepsin A. Pepsinogen/pepsin C was confirmed by Western blot analyses. In a multivariate logistic regression, men were more likely to have airway pepsin (OR, 12.71, P = .029).
Enzymatically active pepsin C, but not the gastric-specific pepsin A, is frequently detected in the lower airways of patients who otherwise have no risk for aspiration. This suggests that nonspecific pepsin assays should be used and interpreted with caution as a biomarker of gastropulmonary aspiration, as pepsinogen C potentially expressed from pneumocytes may be detected in airway samples.
尽管在正常对照人群中缺乏验证,但气道胃蛋白酶已被越来越多地用作胃肺吸入的潜在敏感和可量化的生物标志物。本研究试图定义成人气道胃蛋白酶的正常水平,并区分胃蛋白酶 A(仅限于胃)和胃蛋白酶 C(可由肺细胞表达)。
我们对在一家三级学术医疗中心接受择期四肢矫形手术的 51 例其他健康成年患者进行了前瞻性研究。在下呼吸道样本在气管插管后和拔管前立即获得。通过酶活性测定直接测量总胃蛋白酶和胃蛋白酶 A 浓度,并随后推导胃蛋白酶 C。通过 Western blot 分析证实胃蛋白酶原/胃蛋白酶 C。次要比较基线特征。
共有 11 例(22%;95%CI=9.9%-33%)检测到气道胃蛋白酶浓度。所有 11 个阳性标本均有胃蛋白酶 C,无任何可检测到的胃蛋白酶 A。通过 Western blot 分析证实胃蛋白酶原/胃蛋白酶 C。在多变量逻辑回归中,男性更有可能出现气道胃蛋白酶(OR,12.71,P=0.029)。
在没有吸入风险的患者的下呼吸道中经常检测到酶活性胃蛋白酶 C,但不是胃特异性胃蛋白酶 A。这表明非特异性胃蛋白酶检测应谨慎用作胃肺吸入的生物标志物,因为气道样本中可能检测到来自肺细胞的潜在表达的胃蛋白酶原 C。